Effects of insulin administration in a group of high-risk, non-diabetic, first-degree relatives of type 1 diabetic patients: An open pilot trial

Diabetic Medicine

Volumn 16, Issue 2, 1999, Pages 160-163

  Rodriguez Villar C ^a   Conget, I ^a   Casamitjana, R ^a   Ercilla, G ^a   Gomis De Barbara, Ramon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Insulin treatment; Prevention; Type 1 diabetes mellitus

Indexed keywords

GLUTAMATE DEHYDROGENASE; HLA DR ANTIGEN; ISOPHANE INSULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FAMILY HISTORY; FEMALE; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 1; FAMILY HEALTH; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PILOT PROJECTS; REFERENCE VALUES; RISK FACTORS;

EID: 0032709521     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00044.x     Document Type: Article

References (15)

1. 1 Faas S, Trucco M. The genes influencing the susceptibility to type 1 diabetes mellitus in humans. J Endocrinol Invest 1994; 17: 477-495.
2. 2 Ziegler AG, Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth GS. Predicting Type 1 diabetes. Diabetes Care 1990; 13: 762-775.
3. 3 Seissler J, Morgenthaler NG, Achenhach P, Lamperer EF, Glawe D, Payton M et al. Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM. Diabetologia 1996; 39: 1351-1356.
4. 4 Atkinson Ma, MacLaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933-937.
5. 5 Bertrand S, Paepe M, Vigeant C, Yale JF. Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. Diabetes 1992; 41: 1273-1277.
6. 6 Keller RJ, Eisenbarth G, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-928.
7. 7 Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993; 9: 289-293.
8. 8 Rodríguez-Villar C, Conget I, González-Clemente JM, Vidal J, Navarro P, Casamitjane R et al. Effects of insulin administration on β-cell function in subjects at high risk for type 1 diabetes mellitus. Metabolism 1996; 45: 1-4.
9. 9 Rodríguez-Villar C, Conget I, Esmatjes E, Levy I, Calvet J, Figuerola D et al. Presence of predictive markers of type 1 prediabetes mellitus in first degree relatives of type 1 diabetes mellitus. Med Clin (Barc) 1996; 107: 371-374.
10. 10 Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205-208.
11. 11 Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci 1996; 93: 956-960.
12. 12 Karounos DG, Bryson JS, Cohen DA. Metabolically inactive insulin analog prevents type 1 diabetes in prediabetic NOD mice. J Clin Invest 1997; 100: 1344-1348.
13. 13 Bingley PJ and Icarus Group. Interactions of age, islet cell antibodies, insulin antibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives. Diabetes 1996; 45: 1720-1728.
14. 14 The DPT-1 Study Group. The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1): implementation of screening and staging of relatives. Transplant Proc 1995; 27: 3377.
15. 15 Coutant R, Carel JC, Timsit J, Boitard C, Bougneres P. Insulin and the prevention of insulin-dependent diabetes mellitus. Diabetes Metab 1997; 23 (Suppl. 3): 25-28